1021 – 1030 of 1570
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2009
-
Mark
Long-term follow-up of RA patients of the Hellenic Biologics Registry: comparison of first versus second anti-TNF-alpha therapy
(
- Contribution to journal › Published meeting abstract
-
Mark
Peptidylarginine deiminases and the pathogenesis of rheumatoid arthritis: a reflection of the involvement of transglutaminase in coeliac disease.
(
- Contribution to journal › Article
-
Mark
C1q Inhibits Immune Complex-Induced Interferon-alpha Production in Plasmacytoid Dendritic Cells A Novel Link Between C1q Deficiency and Systemic Lupus Erythematosus Pathogenesis
(
- Contribution to journal › Article
-
Mark
Measure for measure. Outcome assessment of arthritis treatment in clinical practice
(
- Thesis › Doctoral thesis (compilation)
-
Mark
Cartilage oligomeric matrix protein (COMP) has a dual role in complement regulation
2009) 12th European Meeting on Complement in Human Disease In Molecular Immunology 46(14). p.2829-2829(
- Contribution to journal › Published meeting abstract
-
Mark
EULAR points to consider for conducting clinical trials in systemic lupus erythematosus: literature based evidence for the selection of endpoints
(
- Contribution to journal › Scientific review
-
Mark
Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year continuation study
(
- Contribution to journal › Article
-
Mark
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial
(
- Contribution to journal › Article
-
Mark
Proteoglycans and more--from molecules to biology.
(
- Contribution to journal › Scientific review
-
Mark
EULAR points to consider for conducting clinical trials in systemic lupus erythematosus
(
- Contribution to journal › Article